New Jersey is poised to create what some have projected to be a $2 billion marketplace centered on the in-state growing, processing, delivery and retailing of adult use cannabis. While this marketplace is ready to launch over the next few quarters, it bears considering how, if at all, the adult use marketplace will impact the Medical Marijuana Program (MMP) and the cannabis medical market in New Jersey.
At the outset, while New Jersey has had a MMP in place since 2010, there are currently only 12 companies who are licensed under the MMP and just 18 dispensaries in the state. The attempt to double the number of licenses and dispensaries in 2019 was waylaid by litigation challenging the evaluation process used by the Department of Health to score applicants. Now the Cannabis Regulatory Commission (CRC) has jurisdiction over both the existing MMP and the adult use marketplace to come. Their initial work includes issuing new MMP licenses after the redo of the challenged scoring methods and could result in the issuance of 24 new MMP licenses.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Not a Bloomberg Law Subscriber?
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]